Nature Communications (Oct 2021)
Characterisation of tumour microenvironment remodelling following oncogene inhibition in preclinical studies with imaging mass cytometry
- Febe van Maldegem,
- Karishma Valand,
- Megan Cole,
- Harshil Patel,
- Mihaela Angelova,
- Sareena Rana,
- Emma Colliver,
- Katey Enfield,
- Nourdine Bah,
- Gavin Kelly,
- Victoria Siu Kwan Tsang,
- Edurne Mugarza,
- Christopher Moore,
- Philip Hobson,
- Dina Levi,
- Miriam Molina-Arcas,
- Charles Swanton,
- Julian Downward
Affiliations
- Febe van Maldegem
- Oncogene Biology Laboratory, The Francis Crick Institute
- Karishma Valand
- Oncogene Biology Laboratory, The Francis Crick Institute
- Megan Cole
- Oncogene Biology Laboratory, The Francis Crick Institute
- Harshil Patel
- Bioinformatics and Biostatistics Science Technology Platform, The Francis Crick Institute
- Mihaela Angelova
- Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute
- Sareena Rana
- Oncogene Biology Laboratory, The Francis Crick Institute
- Emma Colliver
- Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute
- Katey Enfield
- Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute
- Nourdine Bah
- Bioinformatics and Biostatistics Science Technology Platform, The Francis Crick Institute
- Gavin Kelly
- Bioinformatics and Biostatistics Science Technology Platform, The Francis Crick Institute
- Victoria Siu Kwan Tsang
- Oncogene Biology Laboratory, The Francis Crick Institute
- Edurne Mugarza
- Oncogene Biology Laboratory, The Francis Crick Institute
- Christopher Moore
- Oncogene Biology Laboratory, The Francis Crick Institute
- Philip Hobson
- Flow Cytometry Science Technology Platform, The Francis Crick Institute
- Dina Levi
- Flow Cytometry Science Technology Platform, The Francis Crick Institute
- Miriam Molina-Arcas
- Oncogene Biology Laboratory, The Francis Crick Institute
- Charles Swanton
- Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute
- Julian Downward
- Oncogene Biology Laboratory, The Francis Crick Institute
- DOI
- https://doi.org/10.1038/s41467-021-26214-x
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 14
Abstract
The tumour microenvironment (TME) may change in response to cancer treatments such as KRAS G12C inhibition, with potential implications for combination therapies. Here, the authors provide an antibody panel and workflow for analysing the TME with imaging mass cytometry in pre-clinical mouse models.
